Stock & Company Details
Biomarin Pharmaceutical Inc. $BMRN
Price:
46,691,331
193M
$11B
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
78.18
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
BMRN technical indicators
Latest Biomarin Pharmaceutical Inc. (BMRN) technical indicators as of 2026-06-30: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
55.72 3.6%
MACD:
0.85 2.7%
SMA 50:
$54.57 0.1%
SMA 200:
$55.69 0.0%
EMA 20:
$56.22 0.2%
Bollinger Bands:
58.83 / 53.65
Stochastic:
67.21 10.4%
ADX 14:
24.92 1.7%
ATR 14:
1.71 1.0%
CCI 20:
62.58 49.4%
OBV:
10.46M 13.8%
ROC 12:
3.02% 13.3%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Finance Bot
Ask your questions
Start by typing a question below.
